The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Aerobic glycolysis promotes tumor immune evasion by hexokinase2-mediated phosphorylation of IκBα
Open accessAbstract
High expression of PD-L1 in tumor cells contributes to tumor immune evasion. However, whether PD-L1 expression in tumor cells is regulated by the availability of nutrients is unknown. Here, we show that in human glioblastoma cells, high glucose promotes hexokinase (HK) 2 dissociation from mitochondria and its subsequent binding and phosphorylation of IκBα at T291. This leads to increased interaction between IκBα and μ-calpain protease and subsequent μ-calpain-mediated IκBα degradation and NF-κB activation-dependent transcriptional upregulation of PD-L1 expression. Expression of IκBα T291A in glioblastoma cells blocked high glucose-induced PD-L1 expression and promoted CD8+ T cell activation and infiltration into the tumor tissue, reducing brain tumor growth. Combined treatment with an HK inhibitor and an anti-PD-1 antibody eliminates tumor immune evasion and remarkably enhances the anti-tumor effect of immune checkpoint blockade. These findings elucidate a novel mechanism underlying the upregulation of PD-L1 expression mediated by aerobic glycolysis and underscore the roles of HK2 as a glucose sensor and a protein kinase in regulation of tumor immune evasion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
T cell receptor antagonist peptides induce positive selection
Hogquist, K. A., Jameson, S. C., Heath, W. R., Howard, J. L., Bevan, M. J., & Carbone, F. R. (1994) · Cell · doi:10.1016/0092-8674(94)90169-4 · Cited by 2,858
MYC regulates the antitumor immune response through CD47 and PD-L1
Casey, S. C., Tong, L., Li, Y., Do, R., Walz, S., Fitzgerald, K. N., Gouw, A. M., Baylot, V., Gütgemann, I., Eilers, M., et al. (2016) · Science · doi:10.1126/science.aac9935 · Cited by 1,403
Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Boussiotis, V. A. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1514296 · Cited by 1,339
New regulators of NF-κB in inflammation
Ghosh, S., & Hayden, M. S. (2008) · Nature Reviews Immunology · doi:10.1038/nri2423 · Cited by 1,334
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Li, C.-W., Lim, S.-O., Xia, W., Lee, H.-H., Chan, L.-C., Kuo, C.-W., Khoo, K.-H., Chang, S.-S., Cha, J.-H., Kim, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms12632 · Cited by 1,091
Nuclear PKM2 regulates β-catenin transactivation upon EGFR activation
Yang, W., Xia, Y., Ji, H., Zheng, Y., Liang, J., Huang, W., Gao, X., Aldape, K., & Lu, Z. (2011) · Nature · doi:10.1038/nature10598 · Cited by 1,028
Self-citationCyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect
Yang, W., Zheng, Y., Xia, Y., Ji, H., Chen, X., Guo, F., Lyssiotis, C. A., Aldape, K., Cantley, L. C., & Lu, Z. (2012) · Nature Cell Biology · doi:10.1038/ncb2629 · Cited by 918
Self-citationPatra, K. C., Wang, Q., Bhaskar, P. T., Miller, L., Wang, Z., Wheaton, W., Chandel, N., Laakso, M., Muller, W. J., Allen, E. L., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.06.014 · Cited by 853
PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis
Yang, W., Xia, Y., Hawke, D., Li, X., Liang, J., Xing, D., Aldape, K., Hunter, T., Alfred Yung, W. K., & Lu, Z. (2012) · Cell · doi:10.1016/j.cell.2012.07.018 · Cited by 846
Self-citationDeubiquitination and Stabilization of PD-L1 by CSN5
Lim, S.-O., Li, C.-W., Xia, W., Cha, J.-H., Chan, L.-C., Wu, Y., Chang, S.-S., Lin, W.-C., Hsu, J.-M., Hsu, Y.-H., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.10.010 · Cited by 793
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA
Coelho, M. A., de Carné Trécesson, S., Rana, S., Zecchin, D., Moore, C., Molina-Arcas, M., East, P., Spencer-Dene, B., Nye, E., Barnouin, K., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.11.016 · Cited by 653
Hexokinase Is an Innate Immune Receptor for the Detection of Bacterial Peptidoglycan
Wolf, A. J., Reyes, C. N., Liang, W., Becker, C., Shimada, K., Wheeler, M. L., Cho, H. C., Popescu, N. I., Coggeshall, K. M., Arditi, M., et al. (2016) · Cell · doi:10.1016/j.cell.2016.05.076 · Cited by 558
Clinical Challenges of Immune Checkpoint Inhibitors
de Miguel, M., & Calvo, E. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.004 · Cited by 540
Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt
Robey, R. B., & Hay, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209595 · Cited by 536
Li, X., Jiang, Y., Meisenhelder, J., Yang, W., Hawke, D. H., Zheng, Y., Xia, Y., Aldape, K., He, J., Hunter, T., et al. (2016) · Molecular Cell · doi:10.1016/j.molcel.2016.02.009 · Cited by 508
Self-citationRegulation of PD-L1 Expression by NF-κB in Cancer
Antonangeli, F., Natalini, A., Garassino, M. C., Sica, A., Santoni, A., & Di Rosa, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.584626 · Cited by 385
The gluconeogenic enzyme PCK1 phosphorylates INSIG1/2 for lipogenesis
Xu, D., Wang, Z., Xia, Y., Shao, F., Xia, W., Wei, Y., Li, X., Qian, X., Lee, J.-H., Du, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2183-2 · Cited by 360
Self-citationCdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
Dorand, R. D., Nthale, J., Myers, J. T., Barkauskas, D. S., Avril, S., Chirieleison, S. M., Pareek, T. K., Abbott, D. W., Stearns, D. S., Letterio, J. J., et al. (2016) · Science · doi:10.1126/science.aae0477 · Cited by 315
Phosphoglycerate Kinase 1 Phosphorylates Beclin1 to Induce Autophagy
Qian, X., Li, X., Cai, Q., Zhang, C., Yu, Q., Jiang, Y., Lee, J.-H., Hawke, D., Wang, Y., Xia, Y., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.01.027 · Cited by 283
Self-citationMetabolic Kinases Moonlighting as Protein Kinases
Lu, Z., & Hunter, T. (2018) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2018.01.006 · Cited by 258
Self-citationYang, W., Xia, Y., Cao, Y., Zheng, Y., Bu, W., Zhang, L., You, M. J., Koh, M. Y., Cote, G., Aldape, K., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.09.028 · Cited by 245
Self-citationEnergy status dictates PD-L1 protein abundance and anti-tumor immunity to enable checkpoint blockade
Dai, X., Bu, X., Gao, Y., Guo, J., Hu, J., Jiang, C., Zhang, Z., Xu, K., Duan, J., He, S., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.037 · Cited by 242
Next-generation immuno-oncology agents: current momentum shifts in cancer immunotherapy
Pan, C., Liu, H., Robins, E., Song, W., Liu, D., Li, Z., & Zheng, L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00862-w · Cited by 241
Subcellular localization of hexokinases I and II directs the metabolic fate of glucose
John, S., Weiss, J. N., & Ribalet, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017674 · Cited by 239
β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion
Du, L., Lee, J.-H., Jiang, H., Wang, C., Wang, S., Zheng, Z., Shao, F., Xu, D., Xia, Y., Li, J., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191115 · Cited by 231
Self-citationUnlocking the Potential of HK2 in Cancer Metabolism and Therapeutics
Garcia, S. N., Guedes, R. C., & Marques, M. M. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867326666181213092652 · Cited by 227
Li, X., Qian, X., Peng, L.-X., Jiang, Y., Hawke, D. H., Zheng, Y., Xia, Y., Lee, J.-H., Cote, G., Wang, H., et al. (2016) · Nature Cell Biology · doi:10.1038/ncb3338 · Cited by 213
Self-citationTong, Y., Guo, D., Lin, S.-H., Liang, J., Yang, D., Ma, C., Shao, F., Li, M., Yu, Q., Jiang, Y., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.04.002 · Cited by 207
Self-citationPTEN Suppresses Glycolysis by Dephosphorylating and Inhibiting Autophosphorylated PGK1
Qian, X., Li, X., Shi, Z., Xia, Y., Cai, Q., Xu, D., Tan, L., Du, L., Zheng, Y., Zhao, D., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.08.006 · Cited by 205
Self-citationEGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation
Lee, J.-H., Liu, R., Li, J., Wang, Y., Tan, L., Li, X.-J., Qian, X., Zhang, C., Xia, Y., Xu, D., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.03.018 · Cited by 202
Self-citationThe PEST Domain of IκBα Is Necessary and Sufficient forin Vitro Degradation by μ-Calpain
Shumway, S. D., Maki, M., & Miyamoto, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.43.30874 · Cited by 201
Programmable base editing of mutated TERT promoter inhibits brain tumour growth
Li, X., Qian, X., Wang, B., Xia, Y., Zheng, Y., Du, L., Xu, D., Xing, D., DePinho, R. A., & Lu, Z. (2020) · Nature Cell Biology · doi:10.1038/s41556-020-0471-6 · Cited by 163
Self-citationCholine kinase alpha 2 acts as a protein kinase to promote lipolysis of lipid droplets
Liu, R. R., Lee, J.-H., Li, J., Yu, R., Tan, L., Xia, Y., Zheng, Y., Bian, X., Lorenzi, P. L., Chen, Q., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.05.005 · Cited by 144
Self-citationA Tumor Agnostic Therapeutic Strategy for Hexokinase 1–Null/Hexokinase 2–Positive Cancers
Xu, S., & Herschman, H. R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-1789 · Cited by 124
Metabolic features of cancer cells
Wang, Y., Xia, Y., & Lu, Z. (2018) · 癌症:英文版 · doi:10.1186/s40880-018-0335-7 · Cited by 121
Self-citationXu, D., Li, X., Shao, F., Lv, G., Lv, H., Lee, J.-H., Qian, X., Zheng, W., Xia, Y., Du, L., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav4570 · Cited by 108
Self-citationNawaz, M. H., Ferreira, J. C., Nedyalkova, L., Zhu, H., Carrasco‐López, C., Kırmızıaltın, S., & Rabeh, W. M. (2018) · Bioscience Reports · doi:10.1042/bsr20171666 · Cited by 87
Xia, Y., Wang, J., Liu, T.-J., Yung, W. K. A., Hunter, T. R., & Lu, Z. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.005 · Cited by 78
Self-citation
Cited by
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 784
The hallmarks of cancer immune evasion
Galassi, C., Chan, T. A., Vitale, I., & Galluzzi, L. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.09.010 · Cited by 565
Zhong, Q., Xiao, X., Qiu, Y., Xu, Z., Chen, C., Chong, B., Zhao, X., Hai, S., Li, S., An, Z., et al. (2023) · MedComm · doi:10.1002/mco2.261 · Cited by 442
Self-citationMetabolic regulation of the immune system in health and diseases: mechanisms and interventions
Hu, T., Liu, C.-H., Lei, M., Zeng, Q., Li, L., Tang, H., & Zhang, N. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01954-6 · Cited by 383
Modulating Glycolysis to Improve Cancer Therapy
Chelakkot, C., Chelakkot, V. S., Shin, Y., & Song, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032606 · Cited by 374
Metadata
- Authors
- Guo, D., Tong, Y., Jiang, X., Meng, Y., Jiang, H., Du, L., Wu, Q., Li, S., Luo, S., Li, M., Xiao, L., He, H., He, X., Yu, Q., Fang, J., & Lu, Z.
- Venue
- Cell Metabolism
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 34
- Issue
- 9
- Pages
- 1312-1324.e6
- ISSN
- 1550-4131 (ISSN-L)
- OpenAlex
- W4292951314
- Cited by
- 423
- References
- 43
- FWCI
- 27.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.